Navigation Links
Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc.
Date:9/15/2010

HAYWARD, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that Leonard C. DeBenedictis, 69, Chief Technology Officer and a member of the company's board of directors, will retire from Solta Medical on October 1, 2010. Mr. DeBenedictis will be available to advise the company through the end of the year and he plans to remain active in the development of other emerging medical technologies.

Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical, Inc. said, "Len has dedicated more than 45 years to the evolution of the laser industry and for the past decade was the driving force behind the breakthrough proprietary technology in our Fraxel® family of lasers. He joined us in 2008 with our acquisition of Reliant Technologies where Len was co-founder and CTO. In his tenure at Solta Medical, Len's leadership resulted in Solta's flagship product for fractional skin resurfacing, the Fraxel re:store® DUAL. In addition, Len has been a key player in forging our personal care product initiative with Philips Consumer Lifestyle and leaves us with an impressive pipeline of innovative products. I want to thank him for all of his contributions to the company."

About Solta Medical, Inc.

Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's three premier brands: Thermage®, Fraxel® and Isolaz®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.


'/>"/>
SOURCE Solta Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
2. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
3. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
4. Quinton Oswald Named Chief Executive Officer of SARcode Corporation
5. ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer
6. Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer
7. SL Industries Names Louis J. Belardi Chief Financial Officer
8. Mark S. Rangell Appointed Chief Operating Officer for Sandata Technologies, LLC
9. Former Singapore EDB Officer, Chew Hwee Yong, Joins Menicon as Chief of Special Projects as Menicon Accelerates its Globalization
10. Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
11. Millennium Laboratories Announces New Chief Operating Officer David Cohen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017  International Biophysics Corporation, a ... , today announced a 34% revenue growth in 2016 ... increase in unit sales.  This growth was fueled by its ... in addition to the expansion of its global sales of ... International Biophysics, CEO, "As we enter our 25 th ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
(Date:2/27/2017)... 27, 2017 Leading Countries, Technologies and Companies ... expected to grow at a CAGR of 8.9% from 2016-2021 and ... at a CAGR of 9.1% from 2016 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
Breaking Medicine Technology:
(Date:2/27/2017)... New Jersey (PRWEB) , ... February 27, 2017 , ... ... highest cancer rates, among all types and genders. And the need for advanced services ... by RWJ and its top-rated cancer care program, in collaboration with their non-profit partners ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards ... of International Social Design Awards. , The 7th A' Social Design Award ... and Institutions worldwide with realized projects and conceptual works. , The first phase ...
(Date:2/26/2017)... , ... February 26, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade ... Area consumers look for home care close to home, and by having city-specific pages, ...
(Date:2/26/2017)... ... ... IndustryArchive.Org . is announcing a new way for B2B Sellers to ... pay for B.A.N.T. quality sales leads based on the Sellers decision to purchase a ... that B2B buyers are controlling the sales process via the Internet and that ad ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will exhibit ... Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, ... to improve Medicaid population health management. , ODH will also have an exhibit booth ...
Breaking Medicine News(10 mins):